Ikena Oncology (Ikena Oncology) Debt-to-Equity : 0.06 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ikena Oncology Debt-to-Equity?

Ikena Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.44 Mil. Ikena Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.30 Mil. Ikena Oncology's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $155.35 Mil. Ikena Oncology's debt to equity for the quarter that ended in Mar. 2024 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ikena Oncology's Debt-to-Equity or its related term are showing as below:

IKNA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.07
Current: 0.06

During the past 5 years, the highest Debt-to-Equity Ratio of Ikena Oncology was 0.07. The lowest was 0.00. And the median was 0.04.

IKNA's Debt-to-Equity is ranked better than
69.94% of 1068 companies
in the Biotechnology industry
Industry Median: 0.15 vs IKNA: 0.06

Ikena Oncology Debt-to-Equity Historical Data

The historical data trend for Ikena Oncology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ikena Oncology Debt-to-Equity Chart

Ikena Oncology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.03

0.04

0.06

Ikena Oncology Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial													0.04	0.03	0.07	0.06	0.06

Competitive Comparison of Ikena Oncology's Debt-to-Equity

For the Biotechnology subindustry, Ikena Oncology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ikena Oncology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ikena Oncology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ikena Oncology's Debt-to-Equity falls into.

Ikena Oncology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ikena Oncology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.558	+	7.18)	/	169.757
	=	0.06

Ikena Oncology's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.443	+	6.302)	/	155.347
	=	0.06

Ikena Oncology (NAS:IKNA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ikena Oncology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ikena Oncology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ikena Oncology (Ikena Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ikena Oncology Inc (NAS:IKNA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Suite 101, Boston, MA, USA, 02210

Website

https://www.ikenaoncology.com

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.

Executives

Owen Hughes	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Jotin Marango	officer: CFO & Head of Corp. Dev.	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Francisco Oliveira	officer: Principal Accounting Officer	IKENA ONCOLOGY, INC., 645 SUMMER STREET, SUITE 101, BOSTON MA 02210
Richard Wooster	director	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Xiaoyan Michelle Zhang	officer: Chief Scientific Officer	C/O IKENA ONCOLOGY, INC., 645 SUMMER STREET SUITE 101, BOSTON MA 02210
Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Maria Koehler	director	C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita	director	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Mark Manfredi	director, officer: President & CEO	C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Maude Tessier	officer: Chief Business Officer	C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Jeffrey Ecsedy	officer: Chief Scientific Officer	C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Atlas Venture Associates Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, Llc	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139